Clinical Trial Search

Primary: Number of Device and Procedure Related Adverse Events — 24 Number of Adverse Events

Primary: Number of Participants With Biochemical Failure at 5 Years — 0; 30 Participants

Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants

Primary: Number of Study Participants Experiencing Treatment-Related Toxicity — 0; 0; 1; 9 Participants

Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants

Primary: Acute Grade 3 (NCI CTC v4.0) or Higher Treatment-related Toxicity Rate. — 0; 0 Participants

Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives

Primary: Keyword Description of Each Biopsy Sample — 89 percentage significant cancers detected

Primary: Number of Participants With Any Grade 2 Toxicity Using Intensity Modulated Radiation Therapy (IMRT) to Treat the At-risk Lymph Nodes in Prostate Cancer ( up to First 10…

Primary: Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA) — 3; 2; 1 Participants

Primary: Average Mean Dose to 90% of DIL Volume — 13.25 Grays

Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants

Primary: Sensitivity and Specificity of High Resolution Versus Standard MRI in Identifying Adverse Histology — 75; 71; 84; 54.8 percent

Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage

Primary: Safety - Evaluate the Frequency of Treatment Related Adverse Events — 30 Participants

Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants

Primary: Late Grade ≥ 3 Gastrointestinal (GI) and Genitourinary (GU) Toxicity of Interest, Using the CTCAE v4.0 — 1; 0 Participants

Primary: Incidence of Grade 3+ Gastrointestinal Toxicity — 0 participants

Primary: Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) — 6; 0 Participants

Primary: Number of Participants With Urinary Toxicity Assessed by CTCAE v4.0 — 33 Participants

Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants

Primary: International Prostate Symptom Score (IPSS) Change — -17.5 units on a scale

Primary: Primary Endpoint (HIFU): Identification of New Cancers — 85; 49 biopsy-proven cancerous zones

Primary: Number of Participants With Negative Biopsies at Month 12 — 28; 17 Participants — p=0.0318

Primary: Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy — .43 proportion of participants

Primary: Number of Lesions With Gleason Score ≥ 7 Identified by Ultrasound Molecular Imaging — 17; 8 number of lesions

Primary: Assess the Ability of 99mTc-MIP-1404 to Detect Prostate Cancer Within the Prostate Gland. — 94.2 % sensitivity

Primary: Micro-Ultrasound Detection of High Grade Prostate Cancer (Gleason Score ≥7) vs. Surgical Pathology — 38; 50 participants

Primary: Biochemical Disease-Free Survival (bDFS), Using Phoenix and ASTRO Definitions — 46; 27; 45; 27 Participants

Primary: Number of Participants With Undetectable Cancer on MRI-guided Biopsy of Ablation Zone Following Treatment — 26 Participants